Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network

Drug and Alcohol Dependence

Volumn 118, Issue 2-3, 2011, Pages 186-193

  Wu, Li Tzy ^a   Ling, Walter ^b   Burchett, Bruce ^a   Blazer, Dan G ^a   Yang, Chongming ^c   Pan, Jeng Jong ^d   Reeve, Bryce B ^e   Woody, George E ^f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Clinical Trials Network; Comorbidity; Item response theory; Latent class analysis; Multiple indicators multiple causes model; Opioid dependence; Polysubstance use; Substance use disorders

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; CLONIDINE;

ADDICTION SEVERITY INDEX; ADULT; AGE; ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMOTIONALITY; ENTROPY; ETHNICITY; FEMALE; GENDER; HIV RISK BEHAVIORAL SCALE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITEM RESPONSE THEORY; LATENT CLASS ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RISK ASSESSMENT; SHORT FORM 36; SOCIAL STATUS; SUBSTANCE ABUSE; THEORY; WELLBEING;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; QUALITY OF LIFE; RISK; RISK-TAKING; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 80053507935     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.03.018     Document Type: Article

References (51)

1. Agrawal A., Lynskey M.T., Madden P.A., Bucholz K.K., Heath A.C. A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions. Addiction 2007, 102:94-104.
2. American Psychiatric Association Rationale for Changes to Substance-Related Disorders-Tentative New Title of New Combined Section: Addiction and Related Disorders 2010, Available from: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=431# (accessed 15.10.10.).
3. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision: American Psychiatric Publishing, Washington, DC.
4. Brands B., Blake J., Marsh D.C., Sproule B., Jeyapalan R., Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J. Addict. Dis. 2008, 27:37-48.
5. Browne M.W., Cudeck R. Alternative ways of assessing model fit. Testing Structural Equation Models 1993, 136-162. Sage Publications, Newbury Park, CA. K.A. Bollen, J.S. Long (Eds.).
6. Bucholz K.K., Heath A.C., Reich T., Hesselbrock V.M., Kramer J.R., Nurnberger J.I., Schuckit M.A. Can we subtype alcoholism? A latent class analysis of data from relatives of alcoholics in a multicenter family study of alcoholism. Alcohol. Clin. Exp. Res. 1996, 20:1462-1471.
7. Carroll K.M., Rounsaville B.J. On beyond urine: clinically useful assessment instruments in the treatment of drug dependence. Behav. Res. Ther. 2002, 40:1329-1344.
8. Copeland A.L., Sorensen J.L. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend. 2001, 62:91-95.
9. Darke S., Hall W., Heather N., Ward J., Wodak A. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS 1991, 5:181-185.
10. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51:253-263. (discussion 267-268).
11. Drake S., Swift W., Hall W., Ross M. Drug use, HIV risk-taking, and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend. 1993, 34:67-70.
12. Gillespie N.A., Neale M.C., Prescott C.A., Aggen S.H., Kendler K.S. Factor and item response analysis DSM-IV criteria for abuse of and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opioids. Addiction 2007, 102:920-930.
13. Goldstein M.F., Friedman S.R., Neaigus A., Jose B., Ildefonso G., Curtis R. Self-reports of HIV risk behavior by injecting drug users: are they reliable?. Addiction 1995, 90:1097-1104.
14. Hu L., Bentler P.M. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct. Equ. Model. 1999, 6:1-55.
15. Hudziak J., Helzer J.E., Wetzel M.W., Kessel K.B., McGee B., Janca A., Przybeck P. The use of the DSM-III-R checklist for initial diagnostic assessments. Compr. Psychiatry 1993, 34:375-383.
16. Kahler C.W., Strong D.R. A Rasch model analysis of DSM-IV alcohol abuse and dependence items in the National Epidemiological Survey on Alcohol and Related Conditions. Alcohol. Clin. Exp. Res. 2006, 30:1165-1175.
17. Kendler K.S., Jacobson K.C., Prescott C.A., Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am. J. Psychiatry 2003, 160:687-695.
18. Kirisci L., Vanyukov M., Dunn M., Tarter R. Item response theory modeling of substance use: an index based on 10 drug categories. Psychol. Addict. Behav. 2002, 16:290-298.
19. Kirisci L., Tarter R.E., Vanyukov M., Martin C., Mezzich A., Brown S. Application of item response theory to quantify substance use disorder severity. Addict. Behav. 2006, 31:1035-1049.
20. Koob G.F. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 2006, 101(Suppl. 1):23-30.
21. Leamon M.H., Gibson D.R., Canning R.D., Benjamin L. Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service. Psychiatr. Serv. 2002, 53:1461-1466.
22. Langenbucher J.W., Labouvie E., Martin C.S., Sanjuan P.M., Bavly L., Kirisci L., Chung T. An application of item response theory analysis to alcohol, cannabis, and cocaine criteria in DSM-IV. J. Abnorm. Psychol. 2004, 113:72-80.
23. Leri F., Bruneau J., Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003, 98:7-22.
24. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., Brigham G., Harrer J., Reid M., Muir J., Buchan B., Orr D., Woody G., Krejci J., Ziedonis D. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1100.
25. Lo Y., Mendell N.R., Rubin D.B. Testing the number of components in a normal mixture. Biometrika 2001, 88:778.
26. McElrath K., Chitwood D.D., Griffin D.K., Comerford M. The consistency of self-reported HIV risk behavior among injection drug users. Am. J. Public Health 1994, 84:1965-1970.
27. McGahan P.L., Griffith J.A., Parante R., McLellan A.T. Composite Scores from the Addiction Severity Index 1982, National Institute on Drug Abuse Project DA02554 and the Veterans Administration, Washington, DC.
28. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index: reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
29. Muthén B. Should substance use disorders be considered as categorical or dimensional?. Addiction 2006, 101(Suppl. 1):6-16.
30. Muthén B., Muthén L.K. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol. Clin. Exp. Res. 2000, 24:882-889.
31. Muthén L.K., Muthén B.O. Mplus: Statistical Analysis with Latent Variables: User's Guide 2007, Muthén and Muthén, Los Angeles.
32. Nylund K.L., Asparouhov T., Muthén B. Deciding on the number of classes in latent class analysis and growth mixture modeling. A Monte Carlo simulation study. Struct. Equ. Model. 2007, 14:535-569.
33. Petry N.M. Reliability of drug users' self-reported HIV risk behaviors using a brief, 11-item scale. Subst. Use Misuse 2001, 36:1731-1747.
34. Rondinelli A.J., Ouellet L.J., Strathdee S.A., Latka M.H., Hudson S.M., Hagan H., Garfein R.S. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009, 104:167-174.
35. Rounsaville B.J., Petry N.M., Carroll K.M. Single versus multiple drug focus in substance abuse clinical trials research. Drug Alcohol Depend. 2003, 70:117-125.
36. Saha T.D., Chou S.P., Grant B.F. Toward an alcohol use disorder continuum using item response theory: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol. Med. 2006, 36:931-941.
37. Strain E.C. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin. J. Pain 2002, 18:S14-S27.
38. Saunders J.B., Schuckit M.A., Sirovatka P.J., Regier D.A. Diagnostic Issues in Substance Use Disorders: Refining the Research Agenda for DSM-IV 2007, American Psychiatric Association, Arlington, VA.
39. Substance Abuse and Mental Health Services Administration Treatment Episode Data Set (TEDS) Highlights-2007 National Admissions to Substance Abuse Treatment Services 2009, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD.
40. Substance Abuse and Mental Health Services Administration Results from the 2009 National Survey on Drug Use and Health: National Findings 2010, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD.
41. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch. Gen. Psychiatry 1998, 55:967-972.
42. Vanyukov M.M., Kirisci L., Moss L., Tarter R.E., Reynolds M.D., Maher B.S., Kirillova G.P., Ridenour T., Clark D.B. Measurement of the risk for substance use disorders: phenotypic and genetic analysis of an index of common liability. Behav. Genet. 2009, 39:233-244.
43. Veilleux J.C., Colvin P.J., Anderson J., York C., Heinz A.J. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin. Psychol. Rev. 2010, 30:155-166.
44. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30:473-483.
45. Wu L.T., Pan J.J., Blazer D.G., Tai B., Brooner R.K., Stitzer M.L., Patkar A.A., Blaine J.D. The construct and measurement equivalence of cocaine and opioid dependences: a National Drug Abuse Treatment Clinical Trials Network (CTN) study. Drug Alcohol Depend. 2009, 103:114-123.
46. Wu L.T., Pan J.J., Blazer D.G., Tai B., Stitzer M.L., Brooner R.K., Woody G.E., Patkar A.A., Blaine J.D. An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study. J. Stud. Alcohol Drugs 2009, 70:414-425.
47. Wu L.T., Parrott A.C., Ringwalt C.L., Yang C., Blazer D.G. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am. J. Addict. 2009, 18:452-461.
48. Wu L.T., Pan J.J., Yang C., Reeve B.B., Blazer D.G. An item response theory analysis of DSM-IV criteria for hallucinogen abuse and dependence in adolescents. Addict. Behav. 2010, 35:273-277.
49. Wu L.T., Pan J.J., Blazer D.G., Tai B., Stitzer M.L., Woody G.E. Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. J. Subst. Abuse Treat. 2010, 38:S70-S79.
50. Wu L.T., Ling W., Burchett B., Blazer D.G., Shostak J., Woody G.E. Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among opioid-dependent patients: results from the Clinical Trials Network. Subst. Abuse Rehabil. 2010, 1:13-22.
51. Wu L.T., Woody G.E., Yang C., Blazer D.G. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Addict. Med. 2011, 5:28-35.